DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
We previously described PASD1 as a new cancer testis antigen in multiple myeloma (MM) that is retained post-therapy, suggesting the use of vaccination strategies to induce anti-PASD1 immunity in a setting of minimal residual disease. We have focused on DNA fusion gene vaccines, coupling fragment C d...
Main Authors: | Joseph-Pietras, D, Gao, Y, Zojer, N, Ait-Tahar, K, Banham, A, Pulford, K, Rice, J, Savelyeva, N, Sahota, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2010
|
Similar Items
-
PASD1 is a potential multiple myeloma-associated antigen.
by: Sahota, S, et al.
Published: (2006) -
Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.
by: Campbell, A, et al.
Published: (2010) -
PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.
by: Cooper, C, et al.
Published: (2006) -
Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
by: Ait-Tahar, K, et al.
Published: (2009) -
Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
by: Ait-Tahar, K, et al.
Published: (2009)